Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Androgen receptor pathway inhibitors like enzalutamide (ENZ) are standard PCa treatments.
• Enzalutamide resistance is a major clinical challenge in castration-resistant prostate cancer.

Purpose of the Study:

• To identify FDA-approved drugs that can overcome enzalutamide resistance in prostate cancer.
• To investigate the potential of artesunate (ART) as a therapeutic agent for enzalutamide-resistant PCa.

Main Methods:

• FDA-approved drug screening was performed to identify novel therapeutic candidates.
• The mechanism of action of artesunate in overcoming enzalutamide resistance was investigated.
• Patient datasets were analyzed to assess the role of c-Myc in enzalutamide resistance.

Main Results:

• Artesunate (ART) was identified as a promising drug for overcoming enzalutamide (ENZ) resistance in prostate cancer.
• ART enhances ENZ efficacy by inducing the degradation of c-Myc.
• Patient data analysis confirmed c-Myc's significant role in the development of ENZ resistance.

Conclusions:

• Artesunate represents a potential therapeutic strategy to combat enzalutamide resistance in prostate cancer.
• Targeting c-Myc degradation may be a viable approach to restore sensitivity to enzalutamide therapy.